Chronic Kidney Disease

The FDA has accepted Akebia Therapeutics' resubmission of the vadadustat NDA for anemia in chronic kidney disease. PDUFA date is March 27, 2024.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.

This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Investigators identified a strong magnitude of association between MAFLD and risk of CKD based on the results of a comprehensive meta-analysis.

CKD-aP patients receiving maintenance hemodialysis reported adverse clinical events in line with their pruritus severity and were found to be at greater risk of all-cause mortality, all-cause hospitalization, and cardiovascular events.

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.

A randomized trial assessing a telehealth intervention suggest such an intervention could improve quality of life among people undergoing dialysis.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

Gerald B. Appel, MD, discusses the changing treatment landscape of IgAN.

Anuja Java, MD, discusses the role of complement inhibitors in transplant patients with C3G.

Carla M. Nester, MD, MSA, FASN discusses recent clinical trials on complement inhibitors for C3G.

Carla M. Nester, MD, MSA, FASN discusses the current therapeutic area for C3G and what is on the horizon.

Anuja Java, MD, discusses barriers to perform kidney biopsies to diagnose immune mediated kidney diseases in community settings.

Sanjeev Sethi, MD, discusses clues in the pathology of kidney biopsies that could lead to a C3G diagnosis.

A panel of glomerular disease specialists discuss the importance of building centers of excellence with expertise on the pathology of C3G.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in C3G.

Carla M. Nester, MD, MSA, FASN, discusses the approach to diagnostic testing in pediatric patients suspected of C3G.

Anuja Java, MD, discusses the diagnostic tests that could lead to a diagnosis of C3G.

Sanjeev Sethi, MD, and Gerald B. Appel, MD, discuss how the kidney biopsy can guide treatment and prognosis in IgAN.

Sanjeev Sethi, MD, discusses the role of the electro microscopy in IgAN.

A prospective study on patients with DR and CKD found no significant effect on renal function shortly after performing fluorescein angiography.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in IgAN.

Anuja Java, MD, discusses the differential diagnosis of C3G.

Anuja Java, MD; Carla M. Nester, MD, MSA, FASN; and Gerald B. Appel, MD, discuss the consequences of a missed or late diagnosis of C3G.

Anuja Java, MD, and Gerald B. Appel, MD, discuss the challenges of managing C3G in their patients.